Scores of state-court claims involving Zantac have been filed in other jurisdictions, as well. The New York lawsuits allege that, while the FDA’s daily allowable limit for NDMA is 96 nanograms, “in a single dose of Zantac, researchers are discovering over 3 million nanograms of NDMA.” This means that an individual taking just one dose of Zantac would be exposed to 31,250 times the daily allowable limit of NDMA, and many regular Zantac users have reported taking multiple doses of the drug virtually every day for years or even decades. Zantac and generic ranitidine were pulled from shelves in April 2020 after it was announced that ranitidine can transform chemically into NDMA, a powerful carcinogen that recently has been implicated in the recall of other drugs, including the popular blood-pressure medication valsartan. The Delaware lawsuits also were filed in mid-September, according to a news release issued by the law firm representing the plaintiffs in those cases.
RANITIDINE LAWSUIT HELIOS LEGAL GROUP PATCH
The New York City lawsuits all were filed on Monday, September 12, The Patch reported. Around the same time, more than 7,000 claimants also brought suits in Delaware state court. Recently, a tranche of 20 such cases were filed in Manhattan civil court, with the plaintiffs alleging that the one-time blockbuster drug gave them cancer. In addition to federal multidistrict litigation (MDL) that has centralized more than 2,000 cases, the makers of Zantac and generic ranitidine also face scores of lawsuits in state courts across the United States. Zantac Lawsuit Update: 20 Zantac Lawsuits Filed in NYC Court Over 7k Claimants Bring Suits in Delaware
0 kommentar(er)
